How could obesity drugs become lifelong? WHO’s urgent plan exposed?

A global health alarm is sounding across Europe as the WHO publishes its first formal guidance on GLP-1 receptor agonists used for obesity and diabetes. The recommendations position weight-loss medicines as a tool, but only when paired with diet, exercise, counselling, and long‑term follow‑up. With more than 890 million adults worldwide classified as overweight or obese, the guidance frames obesity as a chronic, relapsing disease that requires sustained, integrated care and ongoing monitoring to protect cardiovascular and metabolic health.